Publications by authors named "Constantin Neagu"

Claim this Profile
D
Discovery of quinazoline HPK1 inhibitors with high cellular potency.
Momar Toure, Theresa Johnson, Bin Li, Ralf Schmidt, Hong Ma, Constantin Neagu

Bioorg Med Chem· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors" [Bioorgan. Med. Chem. Lett. 50 (2021) 128352].
Yufang Xiao, Bayard R Huck, Ruoxi Lan, Lizbeth DeSelm, Xiaoling Chen, Constantin Neagu

Bioorg Med Chem Lett· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors.
Yufang Xiao, Bayard R Huck, Ruoxi Lan, Lizbeth DeSelm, Xiaoling Chen, Constantin Neagu

Bioorg Med Chem Lett· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.
Lizbeth DeSelm, Bayard Huck, Ruoxi Lan, Constantin Neagu, Justin Potnick

J Med Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
Hui Qiu, Zahid Ali, Andrew Bender, Richard Caldwell, Yi-Ying Chen, Constantin Neagu

Bioorg Med Chem· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large-Scale Assessment of Binding Free Energy Calculations in Active Drug Discovery Projects.
Christina E M Schindler, Hannah Baumann, Andreas Blum, Dietrich Böse, Hans-Peter Buchstaller, Constantin Neagu

J Chem Inf Model· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
Hui Qiu, Lesley Liu-Bujalski, Richard D Caldwell, Ariele Viacava Follis, Anna Gardberg, Constantin Neagu

Bioorg Med Chem Lett· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
Richard Caldwell, Lesley Liu-Bujalski, Hui Qiu, Igor Mochalkin, Reinaldo Jones, Constantin Neagu

Bioorg Med Chem Lett· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
Hui Qiu, Lesley Liu-Bujalski, Richard D Caldwell, Ariele Viacava Follis, Anna Gardberg, Constantin Neagu

Bioorg Med Chem Lett· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.
Kim M Andrews, David A Beebe, John W Benbow, David A Boyer, Shawn D Doran, Constantin Neagu

Bioorg Med Chem Lett· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.
Karen A Atkinson, Elena E Beretta, Janice A Brown, Mayda Castrodad, Yue Chen, Constantin Neagu

Bioorg Med Chem Lett· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of novel calcium sensing receptor negative allosteric modulators.
Gayatri Balan, Jonathan Bauman, Samit Bhattacharya, Mayda Castrodad, David R Healy, Constantin Neagu

Bioorg Med Chem Lett· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis